12/18
02:52 pm
kytx
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]
Low
Report
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]
12/17
09:24 am
kytx
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Medium
Report
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
12/16
07:19 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/15
04:05 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.
12/15
04:01 pm
kytx
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
12/15
12:07 pm
kytx
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]
Low
Report
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]
12/15
10:23 am
kytx
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease [Yahoo! Finance]
Medium
Report
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease [Yahoo! Finance]
12/15
06:40 am
kytx
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]
Low
Report
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]
12/15
06:30 am
kytx
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Low
Report
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
12/14
03:02 pm
kytx
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome [Yahoo! Finance]
High
Report
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome [Yahoo! Finance]
12/14
02:30 pm
kytx
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
High
Report
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
12/13
01:10 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
High
Report
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
12/12
10:36 am
kytx
2 ‘Strong Buy' Biotech Stocks With 208% to 329% Upside Potential [Yahoo! Finance]
Medium
Report
2 ‘Strong Buy' Biotech Stocks With 208% to 329% Upside Potential [Yahoo! Finance]
12/9
04:25 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/4
09:08 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/25
01:53 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
12:28 pm
kytx
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
Medium
Report
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
11/12
07:10 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/12
04:05 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
11/12
01:27 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
08:00 am
kytx
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Low
Report
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
11/3
08:00 am
kytx
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
Medium
Report
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
10/29
01:05 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
10/29
06:30 am
kytx
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Medium
Report
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
10/27
08:06 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its price target raised by analysts at HC Wainwright from $10.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its price target raised by analysts at HC Wainwright from $10.00 to $20.00. They now have a "buy" rating on the stock.